Change in the biologic pattern of the migraine with aura after the use of tetrabenazine: Case report;Mudanca no padrao biologico da migranea com aura apos a utilizacao da tetrabenazina: Relato de caso

Arquivos de Neuro-Psiquiatria

Volumn 58, Issue 2 B, 2000, Pages 566-571

  Piovesan, Elcio Juliato ^a   Lange, Marcos Cristiano ^a   Ghizoni Teive, Hélio Aurélio ^a   Tatsui, Cláudio Esteves ^a   Kowacs, Pedro André ^a   Piovesan, Liciane Maia ^a   Werneck, Lineu Cesar ^a  

^a NONE

Author keywords

Dopamine; Migraine; Prophylaxis; Tetrabenazine

Indexed keywords

DOPAMINE RECEPTOR; TETRABENAZINE; ADRENERGIC RECEPTOR AFFECTING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DOPAMINERGIC SYSTEM; DRUG EFFECT; DYSTONIA; EPILEPTIC AURA; HUMAN; MALE; MIGRAINE; TREATMENT OUTCOME; MIGRAINE WITH AURA; PATHOPHYSIOLOGY;

ADRENERGIC UPTAKE INHIBITORS; ADULT; DOPAMINE ANTAGONISTS; DYSTONIA; HUMANS; MALE; MIGRAINE WITH AURA; TETRABENAZINE;

EID: 0034201924     PISSN: 0004282X     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0004-282x2000000300027     Document Type: Article

References (42)

1. Sicuteri F. Dopamine, the second putative protagonist in headache. Headache 1977;17:129-131.
2. 2) Nco/l alleles. Neurology 1997;49:201-206.
3. 4 receptor genes and migraine without aura in a Sardinian sample. Cephalalgia 1997;17:329.
4. Headache Classification Committee of the International Headache Society. Classification. Diagnóstic criteria of headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(Suppl-7).
5. Del Zompo M, Cherchi A, Palmas MA, et al.. Association between dopamine receptor genes and migraine without aura in a Sardinian sample. Neurology 1998;51:781-786.
6. Peroutka SJ. Dopamine and migraine. Neurology 1997;49:650-656.
7. Russell MB, Rasmussen BK, Fenger K, Olesen J. Migraine without aura and migraine with aura are distinct entities: a study of four hundred and eighty-four male and female migraineurs from the general population. Cephalalgia 1996;16:239-245.
8. Bickerstaff ER, Birm MD. Impairment of consciousness in migraine. Lancet 1961;2:1057-1059.
9. Montastruc P, Damase-Michel C, Montastruc JL. Apomorphine potentiates vagal bradycardia. Fur J Pharmacol 1989;166:511-514.
10. Blin O, Azulay JP, Masson G, Aubrespy G, Serratrice G. Apomorphine-induced yawning in migraine patients: enhanced responsiveness. Clin Neuropharmacol 1991;14:91-95.
11. Fanciullacci M, Mechelacci S, Curradi C, Sicuteri F. Hyperresponsiveness of migraine patients to the hypotensive action of bromocriptine. Headache 1980;20:99-102.
12. Lorenlz IT. A survey of headache in Parkinson's disease. Cephalalgia 1989;9:83-86.
13. Van Hilten JJ. The migraine-dopamine link: do migraine and Parkinson's disease coexist? Clin Neurol Neurosurg 1992;94(Suppl):S168-170.
14. Noble EP. The gene that rewars alcoholism. Sci Med 1996;3:52-61.
15. Andersch B, Hahn L, Wendstam C, Ohman R, Abrahamsson L. Treatment of premenstrual tension syndrome with bromocriptine. Acta Endocrinol (Copenh) 1978;216(Suppl):165-174.
16. Andersen AN, Larsen JF, Steenstrup OR, Svendstrup B, Nielsen J. Effect of bromocriptine on the premenstrual syndrome: a double-blind clinical trial. Br J Obstet Gynaecol 1977;84:370-374.
17. Herzog AG. Continuous bromocriptine therapy in menstrual migraine. Neurology 1997;48:101-102.
18. Canonico PL, Scapagnini U, Genazzani E, Zanotti A. Dihydroergokryptine (DEK) in the prophylaxis of common migraine: double-blind clinical study vs placebo. Cephalalgia 1989;9(Suppl 10):445-447.
19. Avella F, Poli A, Ambrosoli L, Girardello R. The effectiveness of a dihydroergocrypune in migraine prophylaxis: a double blind clinical study vs placebo. Cephalalgia 1997;17:435.
20. Pfaffenrath V, Ocstreich W, Haase W. Flunarizine (10 and 20 mg) i.v. versus placebo in the treatment of acute migraine attacks: a multi-center double-blind sindy. Cephalalgia 1990;10:77-81.
21. Piccini P, Nuti A, Paoletti AM, Napolitano A, Melis GB, Bonuccelli U. Possible involvement of dopaminergic mechanisms in the antimigraine action of flunarizine. Cephalalgia 1990;10:3-8.
22. Soyka D, Taneri Z, Oestreich W, Schmidt R. Flunarizine i.v. in the acute treatment of common or classic migraine attacks: a placebo-controlled double blind trial. Headache 1989;29:21-27.
23. Cupini LM, Troisi F, Placidi F, et al.. Does the antimigraine action of flunarizine involve the dopaminergic system? A clinical-neuroendocrinological study. Cephalalgia 1999;19:27-31.
24. Coppola M, Yealy DM, Leibold RA. Randomized, placebo-controlled evaluation of prachlorperazine versus metoclopramide for emergency department treatment of migraine headache. Ann Emerg Med 1995;26:541-546.
25. Fisher H. A new approach to emergency department therapy of migraine headache with intravenous haloperidol: a case series. J Emerg Med 1995;13:119-122.
26. Jones J, Sklar D, Dougherty J, White W. Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache. JAMA 1989;261:1174-1176.
27. Amery WK, Waelkens J. Prevention of the last chance: an alternative pharmacologic treatment of migraine. Headache 1983;23:37-38.
28. Pearson SJ, Reynolds GP. Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease. Neuropharmacology 1988;27:717-719.
29. Login IS, Cronin MJ, MacLeod RM. Tetrabenazine has properties of a dopamine receptor antagonist. Ann Neurol 1982;12:257-262.
30. Reches A, Burke RF, Kuhn CM, Hassan MN, Jackson VR, Fahn S. Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain. J Pharmacol Exp Ther 1983;225:515-521.
31. Pletscher A, Brossi A, Gey KF. Benzoquinolizine derivatives: a new class of monoamine-decreasing drugs with psychotropic action, Int Ver Neurobiol 1962;4:275-306.
32. Ferrari MD, Odink J, Tapparelli C, Van Kempen GM, Pennings EJ, Bruyn GW. Serotonin metabolism in migraine Neurology 1989;39:1239-1242.
33. Chugani DC, Niimura K, Chaturvedi S, Muzik O, Fakhouri M, Lee ML, Chugani HT. Increased brain serotonin synthesis in migraine. Neurology 1999;53:1473-1479.
34. Martucci N, Manna V, Agnoli A. Antidepressant drugs and migraine. Cephalalgia 1985;5(Suppl 2):225-228.
35. Fahn S. Long-term treatment of tardive dyskinesia with presynaptically acting dopamin-depleting agents. Adv Neurol 1983;37:267-276.
36. Jankovic J, Oman J. Tetrabenazine therapy of dystonia, chorea, ties and other dyskinesias. Neurology 1988;38:391-394.
37. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997;48:358-362.
38. Nakamura K, Kuntzman R, Maggio AC, Angulis V, Conney AH. Influence of 6-hydroxydopamine on the effect of morphine on the tail-flick latency. Psychopharmacologia 1973;31:177-189.
39. Gupta YK, Chugh A, Seth SD. Opossing effect of apomorphine on antinociceptive activity of morphine: a dose-dependent phenomenon. Pain 1989;36:263-269.
40. Sandor NT, Lendvai B, Vizi LS. Effect of selective opiate antagonist on striatal acetylcholine and dopamine release. Brain Res Bull 1992;29:369-373.
41. Henryk-Gutt R, Rees WL. Psychological aspects of migraine. J Psychosom Res 1973;17:141-153.
42. Selby G, Lance JW. Observations on 500 cases of migraine and aallied vascular headache. J Neurol Neurosurg Psychiatry 1960;23:23-32.